IDO1 and cancer: The expression of PD-L1 and IDO1 and the clinicopathological impact of PD-L1 and IDO1 co-expression have recently been investigated in several malignant tumors, such as lung cancer23–28, renal cell carcinoma29, thyroid cancer30, and osteosarcoma20.